FuzzyBot: Importing a new version from external source

2024-02-04T03:09:12Z

Importing a new version from external source

New page

==SGLT2 inhibitors==
{{Main|Gliflozin}}
[[SGLT2 inhibitor]]s block the sodium-glucose linked transporter 2 proteins in [[renal tubule]]s of [[nephron]]s in kidneys, reabsorption of glucose in into the renal tubules, promoting excretion of glucose in the urine. This causes both mild weight loss, and a mild reduction in blood sugar levels with little risk of hypoglycemia. Oral preparations may be available alone or in combination with other agents. Along with GLP-1 agonists, they are considered preferred second or third agents for type 2 diabetics sub-optimally controlled with metformin alone, according to most recent clinical practice guidelines. Because they are taken by mouth, rather than injected (like GLP-1 agonists), patients who are [[Fear of needles|injection-averse]] may prefer these agents over the former. They may be considered first line in diabetic patients with cardiovascular disease, especially [[heart failure]], as these medications have been shown to reduce the risk of hospitalization in patients with such comorbidities. Because they are not available as generic medications, however, cost may limit their feasibility for many patients. Furthermore, there has been growing evidence that the effectiveness and safety of this drug class could depend on genetic variability of the patients.

Translations:Diabetes medication/49/en - Revision history

FuzzyBot: Importing a new version from external source